Drugs / RWJ-445380
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00425321 | Dec 2006 → Jan 2008 | rheumatoid arthritis | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00396422 | Sep 2006 → Mar 2007 | psoriasis | Alza Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RWJ-445380 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00425321 ↗ |
| Action | Inhibit | “RWJ-445380 Cathepsin-S Inhibitor” NCT00425321 ↗ |
| Route | Oral | “Patients will receive an oral capsule daily for up to 12 weeks.” NCT00396422 ↗ |